Mokshasree Atluri, DO
Obstetrics/Gynecology · Carmichael
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 8 years
- Graduated 2018
Offices
2 locations · Kamras and Polansky Medical Corporation · Chapa-De Indian Health Program, Inc.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Atluri’s office at (530) 887-2800 to ask if they take your plan before you enroll.
State licence records
1 licence
- Illinois 125073298Temporary Medical Permit · since 2020 · expires 2021-06-30Specialty on the licence: Obstetrics and GynecologyExpiredNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Original Medicare doctor bills
$3,267
Medicare paid this office $3,267 for 19 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
19 Original Medicare patients in 2024. Average age 66 · Women 100% · Health risk score 1.39. Sicker patients than 9 in 10 peers; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 68%.
The office billed $10,560, Medicare allowed $4,305 and paid $3,267; for 35 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$10,204 in 2024
Medicaid paid $10,204 for 1,615 billed services this clinician did in 2024, up to 65 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Prenatal care, at-risk enhanced service; antepartum management | 435 | $5,915 |
| OBSTETRICAL CARE | 13 | $1,089 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 40 | $625 |
| Patient education, not otherwise classified, non-physician provider, individual, per session | 351 | $604 |
| Short return visit (20+ min) | 59 | $560 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 323 | $528 |
| Prenatal care, at-risk assessment | 13 | $511 |
| Prenatal care, at-risk enhanced service; education | 15 | $219 |
| FETAL NON-STRESS TEST | 37 | $133 |
| URINE PREGNANCY TEST | 12 | $12 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 13 | $7 |
| Subsequent prenatal care visit (Prenatal) [Excludes: patients who are seen for a condition unrelated to pregnancy or prenatal care (eg, an upper respiratory infection; patients seen for consultation only, not for continuing care)] | 304 | $0 |
| 2024 | 1,615 | 12 | 65 | $10,204 |
Drugs they prescribed that Part D paid
$2,871
Pharmacies billed $2,871 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
40 generic and 13 brand-name prescriptions · $2,871 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 16 | $860 | $39 |
Year by year
| 2024 | 53 | 28 | None | 25% | $2,871 |
| 2023 | 32 | 16 | 0% (0) | None | $2,638 |
| 2020 | 19 | 14 | 0% (0) | None | $4,114 |
| 2019 | 20 | 16 | None | 0% | $1,778 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Estradiol | 11 | $852 | $77 |
Money from drug and device companies
$41 in 2025
| 2025 | 2 | 3 | None | $41 |
| 2024 | 1 | 1 | None | $13 |
| 2023 | 3 | 4 | None | $73 |
| 2022 | 1 | 1 | None | $27 |
| 2021 | 1 | 1 | None | $97 |
| 2019 | 1 | 1 | None | $110 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $25 | 1 payment
|
| Mayne Pharma Commercial | None | $16 | 2 payments
|
See all 3 published payments
| Astellas Pharma US | Meals · 2025-09-09 | Veozah | $25 |
| Mayne Pharma Commercial | Meals · 2025-06-12 | None | $9 |
| Mayne Pharma Commercial | Meals · 2025-01-07 | None | $8 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $13
| Aspira Women's Health | Ova1 | $13 | 1 payment
|
2023: $73
| Organon | Nexplanon | $26 | 2 payments
|
| AbbVie | Orilissa | $26 | 1 payment
|
| Hologic Sales and Service | Aptima | $22 | 1 payment
|
2022: $27
| Daiichi Sankyo | Injectafer | $27 | 1 payment
|
2021: $97
| AbbVie | Humira | $97 | 1 payment
|
2019: $110
| AbbVie | None | $110 | 1 payment
|
Professional record
- NPI
- 1366947772
- Licence
- CA 20A20128, IL 125.073298Illinois 125073298: Expired
- Group
- Kamras and Polansky Medical Corporation · Chapa-De Indian Health Program, Inc.
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Student in a training program (390200000X)
- Mailing address
- 5821 Jameson Ct, Carmichael, CA, 95608
- NPI first listed
- 2018-03-27
- NPI last updated
- 2022-08-18
- NPI record certified
- 2022-08-18
This is when the NPI record was last certified, not a medical board exam.